168 related articles for article (PubMed ID: 7971442)
1. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
[TBL] [Abstract][Full Text] [Related]
2. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
3. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
4. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
5. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
6. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
7. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
8. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
[TBL] [Abstract][Full Text] [Related]
9. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
10. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
11. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
13. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
[TBL] [Abstract][Full Text] [Related]
14. MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation.
Sansone R; Di Martino D; Lanino E; Dini G; Massimo L; Tonini GP
Bone Marrow Transplant; 1991; 7 Suppl 3():133-5. PubMed ID: 1855077
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
16. Surgical aspects of N-myc oncogene amplification of neuroblastoma.
Nakagawara A; Ikeda K; Yokoyama T; Tsuda T; Higashi K
Surgery; 1988 Jul; 104(1):34-40. PubMed ID: 3388178
[TBL] [Abstract][Full Text] [Related]
17. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
18. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
19. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).
Lorenzana AN; Zielenska M; Thorner P; Gerrie B; Weitzman S; Squire J
Pediatr Pathol Lab Med; 1997; 17(6):875-83. PubMed ID: 9353827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]